-
Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report
-
This report was prepared by Clifford Goodman, Roy Ahn, Rick Harwood, Deborah Ringel, Kareen Savage, Daniel Mendelson, and Robert Rubin of The Lewin Group. Other staff that contributed to the report included Ansari Ameen, Dawn Bartoszewicz, Timothy Field, Doug Fountain, and George Steinfels of The Lewin Group. This report was prepared under contract for the Office of Health Policy, Office of the Assistant Secretary for Planning and Evaluation, Department of Health and Human Services (202-690-6870). The content of this report is solely the responsibility of The Lewin Group. For more information, please contact Clifford Goodman at 703-218-5500.
-
Executive Summary
-
Introduction
-
Study Methods
-
Market Analysis for a Prospective Cocaine Medication
-
Scenarios of Company Decision Making
-
Case Studies: LAAM, Naltrexone, Clozapine, and Nicorette
-
Market Barriers to the Development of COCAINE Pharmacotherapies
-
Conclusions
-
References
-
Appendix A: Market Analysis Model
-
Appendix B: Summaries of Primary Studies on Need for Cocaine Treatment
-
Appendix C: Need For Substance Abuse Treatment
-
Appendix D: Literature Search Strategies For Case Study Reports Of LAAM, Naltrexone, Clozapine, And Nicorette
-
Appendix E: Selection Criteria And Discussion Guide For Interviews With Private Firms
-
